文献速递腹部MR

基于术前MRI特征预测胰腺神经内分泌肿瘤术后复发

Prediction of recurrence after surgery based on preoperative MRI features in patients with pancreatic neuroendocrine tumors.
PubMed 文献 · Eur Radiol · 2021-10-13

回顾性纳入99例术前行MRI检查并接受手术的胰腺神经内分泌肿瘤患者,评估MRI特征与术后复发及无病生存的关系。中位随访40.4个月,复发率12.1%。多因素分析显示,门脉期等-低强化、胆总管或主胰管扩张、大血管侵犯及较大肿瘤与复发和较差的无病生存相关。

要点

  • 门脉期等-低强化和胆胰管扩张是术后2年内复发的独立预测因素。
  • 大血管侵犯(静脉或动脉)显著增加早期复发风险并影响无病生存。
  • 肿瘤较大与复发及较差的无病生存相关,术前MRI评估应重点关注这些特征。

关键影像表现/征象

  • 门脉期等-低强化与术后2年内复发相关(OR 51.89 [1.73-1557.89], p=0.02)。
  • 胆总管或主胰管扩张与术后2年内复发相关(OR 10.49 [1.35-81.64], p=0.03)。
  • 大静脉侵犯与术后1年内复发相关(OR 10.76 [1.14-101.85], p=0.04)。
  • 大动脉侵犯与较差的无病生存相关(HR 42.90 [3.66-502.48], p=0.003)。

诊断标准与关键数值

  • 术后1年内复发的独立预测因素:大静脉侵犯(OR 10.76 [1.14-101.85], p=0.04)。
  • 术后2年内复发的独立预测因素:门脉期等-低强化(OR 51.89 [1.73-1557.89], p=0.02)、胆总管或主胰管扩张(OR 10.49 [1.35-81.64], p=0.03)、较大肿瘤(OR 1.05 [1.00-1.10], p=0.046)。
  • 较差无病生存的独立预测因素:门脉期等-低强化(HR 21.36 [2.01-197.77], p=0.01)、胆管扩张(HR 5.22 [1.46-18.68], p=0.01)、大动脉侵犯(HR 42.90 [3.66-502.48], p=0.003)、较大肿瘤(HR 1.04 [1.01-1.06], p=0.01)。
  • 平均无病生存期116.4±18.5个月,5年无病生存率85.7%。

临床应用与阅片要点

  • 术前MRI报告中应描述肿瘤大小、强化方式(特别是门脉期)、血管侵犯(静脉和动脉)以及胆总管/主胰管扩张情况。
  • 对于门脉期等-低强化、胆胰管扩张或大血管侵犯的患者,提示临床术后复发风险较高,可能需要更密切随访。

局限性

  • 回顾性研究设计,样本量有限(99例),复发事件数较少(12例),可能导致统计效能不足和结果不稳定。
  • 单中心研究,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate useful MRI features in pancreatic neuroendocrine tumor (PNET) patients for predicting recurrence and its timing after surgery.

METHODS: A total of 99 patients with PNET who underwent MRI and surgery from 2000 to 2018 were enrolled. Two radiologists independently assessed MRI findings, including size, location, margin, T1 and T2 signal intensity, enhancement patterns, common bile duct (CBD) or main pancreatic duct (MPD) dilatation, vascular invasion, lymph node enlargement, DWI, and ADC value. Imaging findings associated with recurrence and disease-free survival (DFS) were assessed using logistic regression analysis and Cox proportional hazard regression analysis.

RESULTS: The median follow-up period was 40.4 months, and recurrence after surgery occurred in 12.1% (12/99). Among them, 6 patients experienced recurrence within 1 year, and 9 patients experienced recurrence within 2 years after surgery. In multivariate analysis, major venous invasion (OR 10.76 [1.14-101.85], p = 0.04) was associated with recurrence within 1 year, and portal phase iso- to hypoenhancement (OR 51.89 [1.73-1557.89], p = 0.02), CBD or MPD dilatation (OR 10.49 [1.35-81.64], p = 0.03) and larger size (OR 1.05 [1.00-1.10], p = 0.046) were associated with recurrence within 2 years. The mean DFS was 116.4 ± 18.5 months, and the 5-year DFS rate was 85.7%. In multivariate analysis, portal phase iso- to hypoenhancement (HR 21.36 [2.01-197.77], p = 0.01), ductal dilatation (HR 5.22 [1.46-18.68], p = 0.01), major arterial invasion (HR 42.90 [3.66-502.48], p = 0.003), and larger size (HR 1.04 [1.01-1.06], p = 0.01) showed a significant effect on poor DFS.

CONCLUSION: MRI features, including size, enhancement pattern, vascular invasion, and ductal dilatation, are useful in predicting recurrence and poor DFS after surgery in PNET. Key Points • MRI features are useful for predicting prognosis in patients with PNET after surgery. • PV or SMV invasion (OR 10.49 [1.35-81.64], p = 0.04) was significantly associated with 1-year recurrence. • Portal phase iso- to hypoenhancement (HR 21.36), CBD or MPD dilatation (HR 5.22), arterial invasion (HR 42.90), and larger size (HR 1.04) had significant effects on poor DFS (p < 0.05).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Han S, Kim JH, Yoo J, et al. Prediction of recurrence after surgery based on preoperative MRI features in patients with pancreatic neuroendocrine tumors. Eur Radiol. 2021. PMID: 34647178. doi:10.1007/s00330-021-08316-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。